New York City、NYにおける濾胞性リンパ腫の臨床試験

New York Cityとその周辺地域（約30マイル以内）の拠点で、濾胞性リンパ腫に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト（英語）

ここで研究参加者を募集していますか？このページの上部に表示できます — 30日間 $99 →

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

被験者募集中第1/2相

Columbia University Medical Center, New York
Weill Cornell Medical College Newyork Presbyterian Hospital, New York
Memorial Sloan Kettering Cancer Center Mskcc, New York

18歳以上 · 全性別 · 2026/10/05更新 · NCT05006716

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

被験者募集中第3相

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York

12歳以上 · 全性別 · 2026/10/02更新 · NCT07215910

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

被験者募集中第1/2相

Research Site, New York
Research Site, New York

18歳以上 · 全性別 · 2026/09/30更新 · NCT06542250

Epco, Zanu, Ritux for R/R FL or MZL

被験者募集中第2相

Memorial Sloan Kettering Cancer Center, New York

18歳以上 · 全性別 · 2026/09/25更新 · NCT06563596

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

被験者募集中第1相

New York University (NYU) Clinical Cancer Center, New York
Weill Cornell Medicine, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

被験者募集中第1/2相

New York University Langone Medical Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

18歳以上 · 全性別 · 2026/09/22更新 · NCT05765812

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

被験者募集中第1相

Columbia University, New York

18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

被験者募集中第3相

Research Site, New York
Research Site, New York
Research Site, New York

18歳〜130歳 · 全性別 · 2026/09/21更新 · NCT06549595

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

被験者募集中第2相

Research Site, New York

18歳以上 · 全性別 · 2026/09/11更新 · NCT06526793

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

被験者募集中第3相

Mount Sinai Medical Center, New York

12歳〜100歳 · 全性別 · 2026/09/11更新 · NCT06784752

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

被験者募集中第3相

Icahn School of Medicine at Mt Sinai, New York

18歳以上 · 全性別 · 2026/09/11更新 · NCT06091254

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

被験者募集中第1相

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594